DiaSorin launched Elastase-1 quantification test to support the diagnosis of chronic exocrine pancreatitis on the automated LIAISON XL platform in CE market. It is also available in the U.S. It is the world’s first automated chemiluminescence immunoassay for determination of fecal pancreatic elastase.
Exocrine pancreatic insufficiency is a pathological condition characterized by exocrine pancreatic enzymes resulting in maldigestion or inability to digest the food and poor absorption of the food. In pancreas exocrine tissue produces an enzyme elastase. Exocrine pancreatic insufficiency is linked with certain disease conditions such as cystic fibrosis, chronic pancreatitis, pancreatic cancer etc. the early diagnosis of chronic exocrine pancreatitis is difficult specifically in early stage of the disease.
According to the Axiom Market Research & Consulting‘s market research analyst the immunoassay segment is expected to propel at a CAGR of 6.46% during the forecast period of 2015-2020. The high prevalence of chronic and lifestyle associated disease and high specificity, sensitivity, and cost-saving nature of immunoassays will be positively impacting the in vitro diagnostic market.
DiaSorin S.p.A was founded in 1968 and headquartered in Saluggia, VC Italy. It is a biotechnology based company operating its business in vitro diagnostic, immunoassay, molecular diagnostic, blood tests, GI stool testing, vitamin D, prenatal screening, and infectious diseases. The company develop, produce and market reagent kits for IVD globally and has its presence in continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers worldwide. The research and development department is focusing on new test in immunoassays to increase efficiency, enabling better management of patients with fast, reliable and clinically actionable assay results.